Intravitreal vascular endothelial growth factors hypertension, proteinuria, and renal injury: a concise review

Purpose of review Nearly 20 years ago, vascular endothelial growth factor (VEGF)inhibitors (VEGFi) were adapted from systemic use from antiangiogenesis roles to intravitreal uses. Initially bevacizumab a murine immunoglobulin was injected ‘off label’ as a treatment for diabetic macular edema and age-related macular degeneration. Throughout the following decade aflibercept and finally ranibizumab were adapted and obtained Food and Drug Administration approval for intravitreal use. Initially systemic absorption was thought to be quite low after intravitreal injections and was quoted as being 200-fold lower than levels postulated to induce significant VEGF inhibition. Pharmacodynamic studies obtained in 2014 and again in 2017 revealed significant systemic absorption and detectable VEGF inhibition, this has since been confirmed in multiple subsequent studies. Recent findings A few case reports of renal dysfunction and glomerular disease related to VEGFi were initially identified. Mixed findings on effects on blood pressure were noted in studies. More recently, 32 cases of de-novo glomerular disease and/or proteinuria exacerbation were identified. New studies have corroborated increased blood pressure, proteinuria exacerbation in patients with pre-existing nephrotic syndrome, and systemic VEGF depletion. Further, the most common lesion of systemic VEGFi nephrotoxicity, thrombotic microangiopathy, has recently been reported by our group. Summary We wil...
Source: Current Opinion in Nephrology and Hypertension - Category: Urology & Nephrology Tags: NOVEL THERAPEUTIC APPROACHES IN NEPHROLOGY AND HYPERTENSION: Edited by Ekamol Tantisattamo, Ramy M. Hanna and Kamyar Kalantar-Zadeh Source Type: research

Related Links:

Journal of Human Hypertension, Published online: 27 January 2022; doi:10.1038/s41371-021-00651-zMalignant hypertension and atypical hemolytic uremic syndrome: a possible continuum between two entities?
Source: Journal of Human Hypertension - Category: Cardiology Authors: Source Type: research
Journal of Human Hypertension, Published online: 27 January 2022; doi:10.1038/s41371-021-00652-yFocus on today’s evidence while keeping an eye on the future: lessons derived from hypertension in women
Source: Journal of Human Hypertension - Category: Cardiology Authors: Source Type: research
ConclusionThe slow firing method using a reinforced triple-row stapler for pancreatic transection is simple, safe, and effective for preventing CR-POPF after LDP.
Source: Surgery Today - Category: Surgery Source Type: research
AbstractPurposeTo evaluate the long-term efficacy of large gastric pouch surgery and revisional surgery in patients with a body mass index (BMI)  
Source: Surgery Today - Category: Surgery Source Type: research
Medtronic announces FDA approval of spinal cord stimulation therapy for treating chronic pain resulting from diabetic peripheral neuropathy /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has received U.S. Food and Drug Administration approval... www.prnewswire.com "Medtronic estimates that up to 800,000 US patients suffer from moderate to severe DPN symptoms that are not resolved through conventional medical management approaches, like drugs. The company views these patients as potential ...
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Pain Medicine Source Type: forums
Two recent papers provide insight into possible risk factors for developing the chronic condition, including autoantibodies and diabetes.
Source: The Scientist - Category: Science Tags: News & Opinion Source Type: news
Conditions:   Vitamin D;   Gestational Diabetes Interventions:   Drug: Vitamin D3;   Drug: The placebo(not contain vitamin D) Sponsor:   Women's Hospital School Of Medicine Zhejiang University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Pulmonary Arterial Hypertension;   Erectile Dysfunction Intervention:   Drug: TPN171H single dose Sponsors:   Vigonvita Life Sciences;   Shanghai Institute of Materia Medica, Chinese Academy of Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   HIV;   Insulin Resistance;   Food Insecurity Intervention:   Other: NOURISH Food Box Sponsors:   University of Oklahoma;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Diabetes;   Appendicitis;   Inflammatory Bowel Diseases Intervention:   Other: Biopsy Sponsors:   Bispebjerg Hospital;   The Novo Nordisk Foundation Center for Basic Metabolic Research Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Age-Related Macular Degeneration (AMD) | Avastin | Diabetes | Endocrinology | Epidemiology | Food and Drug Administration (FDA) | Hypertension | Lucentis | Nephrotic Syndrome | Proteinuria | Ranibizumab Injection | Study | Urology & Nephrology